CAPS - calcyphosine Gene
Species: Canis lupus familiaris (sub-species: familiaris)
Gene Type: protein coding
Gene ID: 403965
CAPS Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001003282.1 | NP_001003282.1 | calcyphosin |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
calcyphosin |
|
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(10)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-109025 | Baloxavir marboxil | Inhibitor | 99.96% | Unkown |
| HY-109025A | Baloxavir | Inhibitor | 99.92% | Unkown |
| HY-A0148A | Halofantrine hydrochloride | Inhibitor | 99.90% | Yes |
| HY-17452A | Cefditoren Pivoxil | Inhibitor | 99.29% | Unkown |
| HY-109025R | Baloxavir marboxil (Standard) | Inhibitor | 99.90% | Unkown |
| HY-17452 | Cefditoren sodium | Inhibitor | 99.70% | Unkown |
| HY-116229 | Gemifloxacin | Inhibitor | / | Unkown |
| HY-A0148 | Halofantrine | Inhibitor | / | Unkown |
| HY-17452AR | Cefditoren Pivoxil (Standard) | Inhibitor | / | Unkown |
| HY-A0148AR | Halofantrine hydrochloride (Standard) | Inhibitor | / | Unkown |
Clinical Phase
Bioactive Molecules
(8)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-D0869 | CAPS | 99.95% | Phase 4 | |
| HY-W751835 | Baloxavir-d4 | 99.27% | Phase 4 | |
| HY-145586 | Onradivir | Inhibitor | 99.53% | Phase 3 |
| HY-145586A | Onradivir monohydrate | Inhibitor | / | Phase 3 |
| HY-143744 | Suraxavir marboxil | Inhibitor | / | Phase 3 |
| HY-139553 | Zunsemetinib | Inhibitor | 99.99% | Phase 2 |
| HY-105172 | TT-232 | Agonist | 98.72% | Phase 2 |
| HY-12914 | V116517 | Antagonist | / | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(221)